CLINICAL STUDY
Combined clonidine–short-ACTH test for the simultaneous assessment of growth hormone reserve and hypothalamic–pituitary–adrenal axis integrity in children

Naomi Weintrob1,2, Elliot Sprecher1, Zeev Josefsberg1,2, Pnina Vardi1,2, Clara Weininger1, Yaffa Aurbach-Klipper1,2, Athalia Pertzelan1,2 and Moshe Phillip1,2

1Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tiqva, and 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract
Objective: To determine the feasibility of using the combined oral clonidine and the short-ACTH test instead of the sometimes dangerous insulin-induced hypoglycemia test as a screening procedure, for the simultaneous assessment of growth hormone reserve and hypothalamic–pituitary–adrenal axis integrity in children with growth retardation.

Design: Evaluative study.

Method: Seventy-three children (52 males) aged 11 ± 3 years with attenuated growth (group 1) were tested by combined clonidine (150 µg/m²) and short-ACTH test (either the standard 250 µg or the low-dose 1 µg/1.73 m²). Thirty-one children received no pretreatment (nonprimed) (subgroup 1NP), and 42 were primed with ethynylestradiol 40 µg/m²/day two days before testing (subgroup 1P). The control group for the short-ACTH test (group 2) consisted of 42 children and adolescents (13 males) aged 12 ± 3 years with early or accelerated puberty or premature closure of epiphyses, who received ACTH only (21 standard, 21 low-dose) with no evidence of adrenal or pituitary pathology.

The peak GH response was compared between the primed and the nonprimed group 1 subjects, and the cortisol levels were compared between the combined test subgroups and the controls. The peak pass level for growth hormone was 10 ng/ml; the peak pass level for cortisol was 520 nmol/l.

Results: Sixty-four of the 73 children in group 1 (87.7%) showed a growth hormone level of ≥10 ng/ml on the first stimulation test, including 26/31 (84%) nonprimed and 38/42 (90.5%) primed. Of the 9 patients who failed the first clonidine test, 4 also failed the second, primed test, including 1/5 nonprimed patients (20%) and 3/4 primed patients (75%). This yielded a GH deficiency/insufficiency rate of 5.5% and a rather low false-positive rate of 13.3% (4/30) for the nonprimed subjects and 2.6% (1/39) for the primed subjects. Peak 30-min cortisol in response to ACTH stimulation was similar in the patients who underwent the 250 µg or the 1 µg test within each group (subgroup 1NP, subgroup 1P and group 2); therefore, the results for the two tests were considered together. Compared with group 2, subgroup 1NP patients had a similar 30-min cortisol response (P = NS), and subgroup 1P patients had a much higher response (P < 0.05) (group 2 = 690 ± 145 nmol/l, subgroup 1NP = 772 ± 195 nmol/l, subgroup 1P = 934 ± 209 nmol/l). However, there was no significant difference in the increment in cortisol response between the three groups.

Conclusions: Our results suggest that the combined clonidine–short-ACTH test is a reliable and safe tool for the simultaneous assessment of growth hormone reserve and hypothalamic–pituitary–adrenal axis integrity in children.

Conclusion
European Journal of Endocrinology 143 105–110

Introduction
The efficient diagnostic assessment of growth hormone (GH) secretion is important in children with growth failure, because GH deficiency is readily treatable. Among the various laboratory methods available, provocative GH testing is the most useful and reliable (1). Being that 10% of patients with idiopathic GH deficiency also have adrenocorticotropic (ACTH) deficiency (2, 3), clinicians have traditionally used either the insulin-induced hypoglycemia (IIH) test (4) or the glucagon test (5) to assess concomitantly GH reserve and the integrity of the...
were evaluated for short stature or growth retardation at age 3 to 15 years (median 11 years), with the following auxological characteristics: height > 2 s.d. score below the mean for age or mid-parental height, height velocity below the 25th percentile for age (> 6 months follow-up), and bone age delay > 2 s.d. for age. Chronic systemic diseases, hyperprolactinemia and hypothyroidism (low thyroxine with or without hypothalamic thyrotropin-releasing hormone pattern were considered diagnostic) were ruled out before GH assessment. These patients underwent clonidine stimulation combined with the short-ACTH test, either the standard (250 μg; n = 34) or the low (1 μg/1.73 m²; n = 39) dose. Forty-two patients (32 males) in group 1 were primed with estrogen (ethynylestradiol 40 μg/m²/day) for two days prior to testing (subgroup 1P) and 31 (20 males) were not primed (subgroup 1NP). These two group 1 subgroups were an outcome of our department’s policy change regarding priming for GH testing (20). Patients who failed to achieve the cut-off growth hormone response on the first stimulation test underwent a repeated primed GH stimulation test, the IIH test (for those older than 4 years), or the glucagon test.

The control group (group 2) consisted of 42 healthy subjects (13 males) aged 6.9 to 17.5 years (median 12 years), who were referred to our Pediatric Endocrinology Clinic for evaluation of early or accelerated puberty or short stature due to premature closure of epiphyses, with no other evidence of pituitary or adrenal pathology. Subjects of this group underwent the short-ACTH stimulation test to rule out nonclassical 21-hydroxylase deficiency. Being that the 30-min 17-hydroxy-progesterone response is similar for the standard 250 μg and the low-dose 1 μg tests (17), we randomly assigned the patients to receive either 250 μg (n = 21) or 1 μg/1.73 m² (n = 21). Some of these data were used for control purposes in our previous study (19).

The study protocol was approved by the Ethics Committee of Rabin Medical Center, and informed consent was obtained from the patient and from the parents.

**Subjects and methods**

**Subjects (Table 1)**

The study population comprised 115 children and adolescents (65 males), of whom 73 (group 1, 52 males) and 42 (group 2) were enrolled. The study protocol was approved by the Ethics Committee of Rabin Medical Center, and informed consent was obtained from the patient and from the parents.

<table>
<thead>
<tr>
<th>Subgroup 1NP (n = 31)</th>
<th>Subgroup 1P (n = 42)</th>
<th>Group 2 (ACTH only) (n = 42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female (n)</td>
<td>20/11</td>
<td>32/10</td>
</tr>
<tr>
<td>Age (year) (mean ± s.d.)</td>
<td>9 ± 3*</td>
<td>12 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13 ± 3</td>
</tr>
<tr>
<td>Pubertal stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepubertal (n)</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>Tanner 2–3 (n)</td>
<td>9</td>
<td>20</td>
</tr>
<tr>
<td>Tanner 4–5 (n)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14</td>
</tr>
</tbody>
</table>

*P < 0.05, significantly younger than subgroup 1P and group 2 patients.*

www.eje.org
Table 2 Growth hormone response to combined clonidine–short-ACTH test in 73 children of group 1. Results are mean ± S.D.

<table>
<thead>
<tr>
<th>GH response</th>
<th>Subgroup 1NP (n = 31)</th>
<th>Subgroup 1P (n = 42)</th>
<th>Whole group (n = 73)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak GH (ng/ml)</td>
<td>n</td>
<td>Peak GH (ng/ml)</td>
<td>n</td>
</tr>
<tr>
<td>GH sufficient</td>
<td>20.7 ± 10.0</td>
<td>18.6 ± 7.5</td>
<td>69</td>
</tr>
<tr>
<td>&lt;10 ng/ml in 1st test</td>
<td>6.2 ± 2.7</td>
<td>6.7 ± 1.5</td>
<td>9</td>
</tr>
<tr>
<td>GH insufficient in 2 tests</td>
<td>2.7</td>
<td>5.5 ± 1.0</td>
<td>4</td>
</tr>
<tr>
<td>False positive*</td>
<td>4/30, 13.3%</td>
<td>1/39, 2.6%</td>
<td>5/69, 7.2</td>
</tr>
</tbody>
</table>

Combined clonidine–short-ACTH test, oral clonidine 150 μg/m² with i.v. ACTH 250 μg (n = 34) or 1 μg/1.73 m² (n = 39).
* Patients failed the first combined test and passed the second, primed, provocative test.

Testing protocol

All tests were carried out in the morning (0830–0900 h) following an overnight fast and 30 min after an indwelling catheter was placed in a forearm vein for slow infusion of isotonic saline.

In the combined test group, a single oral dose of clonidine (Normopresan, Rafa, Jerusalem, Israel), 150 μg/m², was administered simultaneously with an intravenous injection of ACTH (1–24) (Synacthen, Ciba-Geigy, Basel, Switzerland), either 250 μg or 1 μg/1.73 m². Blood samples were withdrawn at 0, 30 and 60 min for cortisol determination and at 0, 30, 60, 90 and 120 min for GH determination. Pass levels were defined as a peak serum GH level of 10 ng/ml (1, 21), and a 30-min serum cortisol concentration of 520 nmol/l (19.4 μg/dl) for the short-ACTH test (16).

The IIH test was performed with intravenous injection of short-acting human insulin, 0.1 U/kg body weight. Sampling for glucose levels was carried out every 15 min, and for GH and cortisol every 30 min, for 120 min. The test was considered adequate for GH and HPA reserve assessment if hypoglycemia of 2.2 mmol/l (40 mg/dl) or less was documented. The glucagon stimulation test was performed with an intramuscular injection of 30 μg/kg. maximum 1 mg glucagon (Novo Nordisk, Bagsvaerd, Denmark). Sampling for glucose, GH and cortisol levels was carried out every 30 min for 240 min.

Hormone assays

Blood samples were immediately separated and kept frozen at −20 °C until assayed. The serum cortisol and GH concentrations were determined with a commercially available solid phase chemiluminescentenzyme immunoassay employing an Immulite automated analyzer (DPC, Los Angeles, CA, USA). The detection limit was 28 nmol/l for cortisol and 0.05 ng/ml for GH. The intra-assay and interassay coefficients of variation were, respectively, 9% and 10.3% with a cortisol level of 110 nmol/l; 6.8% and 9.9% with a cortisol level of 640 nmol/l; 3.7% and 3.8% with a GH level of 2.7 ng/ml; and 4.0% and 3.3% with a GH level of 12 ng/ml. Serum glucose was measured by the GOD-PAP (Boehringer Manheim GmbH, Manheim, Germany) enzymatic colorimetric test on a Hitachi 717/911 device (Hitachi, Osaka, Japan) with typical interassay coefficients of variation of 0.7–3%.

Statistical analysis

Within-group and between-group differences between the tests were assessed with analysis of variance (ANOVA); either pre-planned contrasts or Dunnet’s test for subcomparisons to controls, were employed as appropriate. Statistical analyses were performed with the JMP software (SAS Institute, Cary, NC, USA) and Excel (Microsoft Corporation, Redmond, WA, USA).

Results

Growth hormone response (Table 2)

Nine of the 73 patients in group 1 (12.3%) had an insufficient response of GH (<10 ng/ml) on the first test, including 5 of the 31 non-primed patients (subgroup 1NP) (16%) and 4 of the 42 primed patients (subgroup 1P) (9.5%). Of the five nonprimed subjects (four males, three prepubertal, one pubertal stage 2, and one prepubertal female) who failed the first test at 2.7, 5.5, 7.0, 7.6 and 8.9 ng/ml, four passed the second (primed) test at 9.9, 10.1, 15.8 and 17.1 ng/ml and only one (20%), a prepubertal male, also failed the second primed test, at 1.3 ng/ml; he is currently being treated with GH. Of the four primed subjects (one prepubertal male, two prepubertal females and one pubertal stage 2 female) who failed the first (primed) test at 4.8, 6.4, 7.4 and 8.2 ng/ml, three (75%) also failed the second (primed) test, at 4.9, 5.0 and 6.7 ng/ml, and only one, a prepubertal female, passed it at 20.2 ng/ml. Considering that failure on two stimulation tests suggests a diagnosis of GH insufficiency, these figures indicate a rather low false-positive rate of 13.3% (4/30) for the nonprimed subjects and 2.6% (1/39) for the estrogen-primed subjects on the first stimulation test. The rate of GH deficiency/insufficiency
among the children with short stature (group 1) was 5.5% (4/73). Regarding the mean peak GH response, following exclusion of the 4 children with GH deficiency, values were similar for the nonprimed (20.7 ± 10 ng/ml) and the primed subgroups (18.6 ± 7.5 ng/ml; P = 0.32) although there was no difference in their pubertal stage distribution (Table 1).

Cortisol levels (Table 3)

The mean 30-min serum cortisol level was similar for the standard and the low-dose tests in all three groups (subgroup 1NP 799 ± 214 nmol/l (n = 19), 728 ± 161 nmol/l (n = 12), P = 0.97; subgroup 1P 910 ± 189 nmol/l (n = 15), 948 ± 222 nmol/l (n = 12), P = 0.59; group 2 725 ± 170 nmol/l (n = 21), 656 ± 112 nmol/l (n = 21), P = 0.12 respectively). Therefore, the findings for the 30-min cortisol response in the 250 µg and 1 µg/1.73 m² stimulation tests within each group/subgroup were considered together.

The 30-min peak cortisol response in group 2 was 690 ± 145 nmol/l. Compared with group 2, subgroup 1NP had a similar mean 30-min peak cortisol response to the ACTH test (772 ± 195 nmol/l, P = NS) whereas subgroup 1P patients showed a much higher response (934 ± 209 nmol/l, P < 0.05). Comparisons of the basal cortisol levels between controls (337 ± 130 nmol/l) and subgroup 1NP (450 ± 205 nmol/l), controls and subgroup 1P (604 ± 230 nmol/l) and subgroups 1NP and 1P, all yielded a statistically significant difference (P < 0.05). However, delta cortisol levels (time 30 min – time 0) between the same groups were not significantly different (Table 3).

All group 1 children passed the standard test. One male patient (1/39, 2.6%) failed the 1 µg test (peak cortisol response of 462 nmol/l). His peak GH response was 16.8 ng/ml, and his repeated 1 µg test peaked at 514 nmol/l.

In group 2, all patients who underwent the 250 µg test (n = 21) showed HPA sufficiency. However, 2/21 (9.5%) who underwent the low-dose test failed, with peak levels of 225 and 265 nmol/l. Their repeated 1 µg tests peaked at 753 and 603 nmol/l respectively.

The only side effect observed for the combined clonidine–ACTH test was drowsiness, which lasted for a few hours. Two male patients had syncope during urination following the test, without any sequelae. This has since been avoided by our asking parents to accompany the children to the toilet until the drowsiness resolves.

Discussion

The present study shows that the combined clonidine–short-ACTH test is a feasible tool for the simultaneous evaluation of the GH and HPA axes. The results for GH confirm the low false-positive rate and safety of the clonidine test described in previous studies of children (8–11). Using the now accepted cut-off value of 10 ng/ml, only 12.3% (9/73) of our population had a below-threshold GH response on the first combined test, a failure rate that falls within the range documented in previous studies for clonidine stimulation alone: 23.2% (11) and 6% (9). Indeed, 4 of the 9 children who failed the first test failed the second one also (either the IIIH or glucagon test); thus 5.5% (4/73) of the short-stature children studied fulfilled the criteria for GH insufficiency/deficiency. As a result, the false-positive rate for the first combined stimulation test was actually only 7.2% (5/69), a figure similar to that found by Lanes and Hurtado (9) who performed the clonidine test only, and lower than that described for the glucagon test (20%), (22) or the IIIH test (12–49%) (9, 11) performed in normally growing children. We conclude that the addition of the ACTH test to the clonidine stimulation test does not influence the GH response.

Table 3 Cortisol levels (nmol/l) in short-ACTH test. Results are means ± S.D.

<table>
<thead>
<tr>
<th>Test</th>
<th>Subgroup 1NP (n = 19)</th>
<th>Subgroup 1P (n = 15)</th>
<th>Group 2 (n = 21) (ACTH only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal (0)</td>
<td>450 ± 205*</td>
<td>604 ± 230*</td>
<td>337 ± 130*</td>
</tr>
<tr>
<td>30-min response</td>
<td>772 ± 195</td>
<td>934 ± 209**</td>
<td>690 ± 145</td>
</tr>
<tr>
<td>30-min – 0***</td>
<td>321 ± 176</td>
<td>330 ± 200</td>
<td>364 ± 134</td>
</tr>
</tbody>
</table>

*30-min cortisol levels in the standard and low dose tests, within each group, were similar and were therefore considered together for each group.

**P < 0.05 comparing all 3 groups; ***P < 0.05 compared with subgroup 1NP and group 2; ****P not significant for all 3 groups.
It should be noted that while clonidine provoked a strong GH response in children (8–12), the various studies in adults have yielded contradictory results; Rahim et al. (7) found clonidine no better than placebo, whereas Grosman et al. (23) and Baranowska (24) reported a GH response similar to ours. Therefore, we refer our results to the pediatric age group.

In agreement with Marin et al. (20), we suggest that priming with sex steroids may reduce the false-positive rate of the GH response to stimulation tests. Eighty-four percent of the nonprimed subjects had a GH response of ≥10 ng/ml, compared with 90.5% of the primed subjects. Following exclusion of the patients who failed the second test too (thereby fulfilling the criteria for GH insufficiency), the false-positive rate was 13.3% for the nonprimed patients and only 2.6% for the primed patients. Marin et al. (20) showed a very high false-positive rate for prepubertal and pubertal stage 2 (61% and 44% respectively), which decreased to zero in stages 4 and 5. Most of our combined test population (96%) was either prepubertal or Tanner stage 2, and all our nonresponsive patients belonged to these two categories. Nevertheless, our failure rate for the nonprimed subjects was much lower – 3/22 (14%) for the prepubertal patients and 1/7 (14%) for the patients in pubertal stage 2 – even though the other study used a lower cut-off point of 7 ng/ml and was conducted in a normally growing population. This large discrepancy might be explained by the different stimulation test used: exercise, arginine and insulin (20) have been found to be less reliable (with a higher false-positive rate) than clonidine (8–11) in children. Furthermore, the laboratory assay used in the earlier work to measure serum GH was a polyclonal RIA, whereas we employed the solid phase chemiluminescent enzyme immunoassay. The variation in GH assays can be as great as two- to threefold (25) among major reference laboratories, stressing again the need to standardize both the stimulation tests and the laboratory assays used for GH reserve assessment and measurement. From our results, we can conclude that the addition of the ACTH test to the clonidine stimulation test does not influence the GH response.

In light of the previous reports on cortisol level suppression by clonidine (9, 12), it is of interest that the peak cortisol value was higher in the combined-test subjects, indicating that clonidine does not interfere with the cortisol response to ACTH. Our results are in line with the studies of Milsom et al. (26) and Lyons et al. (27) showing that ACTH and cortisol responses to corticotropin-releasing hormone stimulation or to stress of surgery are not affected by the concomitant or pretreatment use of clonidine. Apparently clonidine, a central alpha-2-adrenergic agonist, by reducing peripheral sympathetic tone, and thereby lowering peripheral levels of noradrenaline (26), has a mild inhibitory effect on ACTH and cortisol secretion which is easily overcome by direct stimulation of the pituitary or adrenal glands.

In both groups, all subjects passed the 250 μg test, and the failure rates for the low-dose ACTH test were also similar (2% for subgroup 1NP and 7% for group 2). In agreement with previous studies, the low-dose ACTH test, which provides more physiological adrenocortical stimulation (28), failed in a small proportion of children to detect an intact HPA axis (18, 29). Results concerning the better sensitivity of the low-dose than the standard-dose short-ACTH test to detect secondary adrenal insufficiency, when comparing them to the IIH test, have been contradictory (18, 29, 30). These differences may be attributed to differences in dose, sampling time, cut-off level and studied population. Whether the 1 μg dose is preferable remains uncertain. Should the low-dose test prove to be a more sensitive tool to detect partial or recent HPA insufficiency, the small decrease in specificity is an acceptable price.

Basal and peak cortisol responses were much higher in the patients primed with sex hormone: the increase was probably secondary to the estrogen-induced increase in cortisol-binding globulin levels. Brien (31) found that this effect occurs in both sexes and is demonstrable within 2 to 4 days. The delta cortisol response, however, was similar for all three groups. The post-priming elevation of both basal and peak cortisol levels raises the possibility that partial HPA insufficiency will be masked. Therefore, we primed five patients with known partial ACTH deficiency by previous IIH test (19), and none of them reached the pass cortisol level of 520 nmol/l (data not shown). Basal cortisol levels were also significantly higher in subgroup 1NP compared with group 2, while peak and delta levels were similar. This difference might be attributed to the younger age of subgroup 1NP and therefore higher stress at testing (Table 1).

The age at testing, the male/female ratio, and the pubertal stage distribution were different between the ACTH only and the combined-test groups. However, since serum cortisol levels do not correlate with either age or gender (32), we assume these differences are irrelevant to the results.

We conclude that the combined clonidine and short-ACTH test is a reliable, safe and easy to perform tool for the simultaneous assessment of GH reserve and the integrity of the HPA axis in children with impaired growth. ACTH does not change the response of GH to clonidine, and clonidine does not interfere with the stimulation of cortisol by ACTH. Further studies of this combination are needed in children with pituitary–hypothalamic disease, in whom HPA insufficiency is more frequent.

Acknowledgements

The authors thank Mrs Gloria Ginzach and Mrs Charlotte Sachs of the Editorial Board, Rabin Medical Center, Beilinson Campus, and Oren Moran for their assistance.

www.eje.org
References


30 Abdu TAM, Elhadd TA, Neary R & Clayton RN. Comparison of the low dose short synacthen test (1 μg), the conventional dose short synacthen test (250 μg), and the insulin tolerance test for assessment of the hypothalamo–pituitary–adrenal axis in patients with pituitary disease. Journal of Clinical Endocrinology and Metabolism 1999 84 838–843.
